Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

OLLIVIER - PHARMA : revenue, balance sheet and financial ratios

OLLIVIER - PHARMA is a French company founded 13 years ago, specialized in the sector Fonds de placement et entités financières similaires. Based in LE POULIGUEN (44510), this company of category PME shows in 2025 a net income positive of 210 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - OLLIVIER - PHARMA (SIREN 792877441)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2016
Revenue N/C N/C N/C N/C N/C N/C N/C N/C N/C
Net income 209 948 € 110 618 € 140 585 € 123 656 € 233 876 € 71 181 € 106 357 € 79 573 € 62 404 €
EBITDA N/C N/C -1 357 € -1 326 € -1 397 € -1 246 € -1 358 € -9 536 € -11 451 €
Net margin N/C N/C N/C N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, OLLIVIER - PHARMA generates positive net income of 210 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 62 k€ -> 210 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

209 948 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 29%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 76%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

28.889%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

75.529%

Solvency indicators evolution
OLLIVIER - PHARMA

Sector positioning

Debt ratio
28.89 2025
2023
2024
2025
Q1: 0.14
Med: 27.24
Q3: 146.28
Average -7 pts over 3 years

In 2025, the debt ratio of OLLIVIER - PHARMA (28.89) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
75.53% 2025
2023
2024
2025
Q1: 17.38%
Med: 54.75%
Q3: 87.41%
Good +8 pts over 3 years

In 2025, the financial autonomy of OLLIVIER - PHARMA (75.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
3.96 years 2023
2023
Q1: 0.0 years
Med: 0.12 years
Q3: 4.47 years
Average

In 2023, the repayment capacity of OLLIVIER - PHARMA (3.96) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 431.87. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

431.866

Liquidity indicators evolution
OLLIVIER - PHARMA

Sector positioning

Liquidity ratio
431.87 2025
2023
2024
2025
Q1: 159.67
Med: 1116.63
Q3: 6512.12
Average -43 pts over 3 years

In 2025, the liquidity ratio of OLLIVIER - PHARMA (431.87) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Interest coverage
-246.06x 2023
2023
Q1: -106.29x
Med: -3.78x
Q3: 0.0x
Average

In 2023, the interest coverage of OLLIVIER - PHARMA (-246.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
OLLIVIER - PHARMA

Positioning of OLLIVIER - PHARMA in its sector

Comparison with sector Fonds de placement et entités financières similaires

Valuation estimate

Based on 170 transactions of similar company sales (all years), the value of OLLIVIER - PHARMA is estimated at 2 176 489 € (range 1 349 106€ - 3 385 126€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
170 transactions
1349k€ 2176k€ 3385k€
2 176 489 € Range: 1 349 106€ - 3 385 126€
NAF 5 all-time

Valuation method used

Net Income Multiple
209 948 € × 10.4x = 2 176 489 €
Range: 1 349 107€ - 3 385 126€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 170 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fonds de placement et entités financières similaires)

Compare OLLIVIER - PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Fonds de placement et entités financières similaires

Frequently asked questions about OLLIVIER - PHARMA

What is the revenue of OLLIVIER - PHARMA ?

The revenue of OLLIVIER - PHARMA is not publicly disclosed (confidential accounts filed with INPI).

Is OLLIVIER - PHARMA profitable?

Yes, OLLIVIER - PHARMA generated a net profit of 210 k€ in 2025.

Where is the headquarters of OLLIVIER - PHARMA ?

The headquarters of OLLIVIER - PHARMA is located in LE POULIGUEN (44510), in the department Loire-Atlantique.

Where to find the tax return of OLLIVIER - PHARMA ?

The tax return of OLLIVIER - PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does OLLIVIER - PHARMA operate?

OLLIVIER - PHARMA operates in the sector Fonds de placement et entités financières similaires (NAF code 64.30Z). See the 'Sector positioning' section above to compare the company with its competitors.